Genomic Damage in Endstage Renal Disease—Contribution of Uremic ToxinsAuthor(s): Nicole Schupp | August Heidland | Helga Stopper
Journal: Toxins ISSN 2072-6651
Volume: 2; Issue: 10; Start page: 2340; Date: 2010;
Keywords: dialysis | genotoxicity | uremic toxins
Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-a. This review provides an overview of genomic damage observed in ESRD patients, focuses on possible underlying causes and shows modulations of the damage by modern dialysis strategies and vitamin supplementation.